Nanjing Leads Biolabs Co., Ltd. Class H (9887) has received a new Buy rating, initiated by CMB International Securities analyst, Jill Wu.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jill Wu has given her Buy rating due to a combination of factors, primarily focusing on the innovative and extensive pipeline of Nanjing Leads Biolabs Co., Ltd. The company is actively developing next-generation immuno-oncology therapies, particularly through its proprietary platforms like LeadsBody and X-body, which are designed to drive continuous drug innovations. These platforms enable the development of promising drug candidates such as LBL-024 and LBL-034, which have shown significant potential in clinical trials.
LBL-024, a 4-1BB-targeted immunotherapy, has demonstrated promising results in clinical trials, including high objective response rates and minimal liver toxicity. It is positioned to become the first of its kind globally, with a broad potential for expanding indications across various tumors. Additionally, LBL-034 has shown favorable safety and efficacy profiles in treating relapsed/refractory multiple myeloma, further supporting the company’s strong pipeline. These developments, combined with a positive financial outlook and a target price derived from a DCF model, underpin Jill Wu’s Buy rating for the company’s stock.